Lewis Warrington

516 total citations
25 papers, 404 citations indexed

About

Lewis Warrington is a scholar working on Psychiatry and Mental health, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Lewis Warrington has authored 25 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Psychiatry and Mental health, 7 papers in Cellular and Molecular Neuroscience and 6 papers in Molecular Biology. Recurrent topics in Lewis Warrington's work include Bipolar Disorder and Treatment (13 papers), Schizophrenia research and treatment (11 papers) and Receptor Mechanisms and Signaling (5 papers). Lewis Warrington is often cited by papers focused on Bipolar Disorder and Treatment (13 papers), Schizophrenia research and treatment (11 papers) and Receptor Mechanisms and Signaling (5 papers). Lewis Warrington collaborates with scholars based in United States, Italy and Canada. Lewis Warrington's co-authors include Antony Loebel, Elliott Richelson, Mona Boules, Abdul H. Fauq, Daniel McCormick, Emilio Sacchetti, Fabio Romeo, Paolo Valsecchi, Alessandro Galluzzo and Cynthia Siu and has published in prestigious journals such as Brain Research, Life Sciences and European Journal of Pharmacology.

In The Last Decade

Lewis Warrington

25 papers receiving 392 citations

Peers

Lewis Warrington
Leif H. Lindstr�m Sweden
B.I. Diamond United States
Celine Teo Canada
Kenneth B. Kashkin United States
J. Bollen Belgium
Dennis Sweitzer United States
John Scott Carman United States
Joseph Pultz United States
Yu-Ping Ning China
Robyn McAskill United Kingdom
Leif H. Lindstr�m Sweden
Lewis Warrington
Citations per year, relative to Lewis Warrington Lewis Warrington (= 1×) peers Leif H. Lindstr�m

Countries citing papers authored by Lewis Warrington

Since Specialization
Citations

This map shows the geographic impact of Lewis Warrington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lewis Warrington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lewis Warrington more than expected).

Fields of papers citing papers by Lewis Warrington

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lewis Warrington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lewis Warrington. The network helps show where Lewis Warrington may publish in the future.

Co-authorship network of co-authors of Lewis Warrington

This figure shows the co-authorship network connecting the top 25 collaborators of Lewis Warrington. A scholar is included among the top collaborators of Lewis Warrington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lewis Warrington. Lewis Warrington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sacchetti, Emilio, et al.. (2009). Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study. Schizophrenia Research. 110(1-3). 80–89. 55 indexed citations
3.
Keck, Paul E., Márcio Versiani, Lewis Warrington, Antony Loebel, & Robert Lynn Horne. (2009). Long-Term Safety and Efficacy of Ziprasidone in Subpopulations of Patients With Bipolar Mania. The Journal of Clinical Psychiatry. 70(6). 844–851. 14 indexed citations
4.
Potkin, Steven G., Peter J. Weiden, Antony Loebel, et al.. (2009). Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. The International Journal of Neuropsychopharmacology. 12(9). 1233–1233. 34 indexed citations
5.
Sacchetti, Emilio, et al.. (2009). Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study. Schizophrenia Research. 113(1). 112–121. 31 indexed citations
6.
Agid, Ofer, et al.. (2008). Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophrenia Research. 102(1-3). 241–248. 27 indexed citations
7.
Warrington, Lewis, et al.. (2007). P.3.c.026 Cognitive effects of ziprasidone and clozapine: results from an 18-week double-blind trial. European Neuropsychopharmacology. 17. S439–S439. 2 indexed citations
8.
Zimbroff, Dan, Lewis Warrington, Antony Loebel, Ruoyong Yang, & Cynthia Siu. (2007). Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. International Clinical Psychopharmacology. 22(6). 363–370. 40 indexed citations
9.
Warrington, Lewis, Ilise Lombardo, Antony Loebel, & Kathleen Ice. (2007). Ziprasidone for the Treatment of Acute Manic or Mixed Episodes Associated with Bipolar Disorder. CNS Drugs. 21(10). 835–849. 19 indexed citations
10.
Ketter, Terence A., et al.. (2007). P.2.e.015 Early onset of antipsychotic action and time course in the treatment of acute bipolar mania. European Neuropsychopharmacology. 17. S384–S385. 1 indexed citations
11.
Warrington, Lewis, et al.. (2006). P.3.c.056 Efficacy of ziprasidone in the treatment of schizoaffective disorder:an analysis of 2 fixed-dose, placebo-controlled trials. European Neuropsychopharmacology. 16. S427–S427. 1 indexed citations
12.
Sacchetti, Emilio, et al.. (2006). P.3.a.019 Efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients:results of a randomized, double-blind, 18-week trial. European Neuropsychopharmacology. 16. S374–S374. 5 indexed citations
13.
Harvey, P.D., et al.. (2004). P.2.140 Cognitive improvement andneuropsychological normalization with ziprasidone or olanzapine: Results of a 6-month study. European Neuropsychopharmacology. 14. S294–S294. 3 indexed citations
14.
Daniel, D.G., S. Brook, Lewis Warrington, Antony Loebel, & Stephen A. Murray. (2004). Intramuscular ziprasidone in agitated patients with bipolar diagnoses. Annals of Emergency Medicine. 44(4). S22–S22. 1 indexed citations
15.
Citrome, Leslie, S. Brook, Lewis Warrington, Antony Loebel, & Francine S. Mandel. (2004). Ziprasidone versus haloperidol for the treatment of agitation. Annals of Emergency Medicine. 44(4). S22–S22. 7 indexed citations
16.
Boules, Mona, Rui Wang, Lewis Warrington, et al.. (2003). Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood–brain barrier. Brain Research. 987(1). 39–48. 22 indexed citations
17.
Boules, Mona, et al.. (2002). Neurotensin analogs Indications for use as potential antipsychotic compounds. Life Sciences. 70(10). 1101–1119. 19 indexed citations
18.
Boules, Mona, Lewis Warrington, Abdul H. Fauq, Daniel McCormick, & Elliott Richelson. (2001). A novel neurotensin analog blocks cocaine- and d-amphetamine-induced hyperactivity. European Journal of Pharmacology. 426(1-2). 73–76. 52 indexed citations
19.
Boules, Mona, Lewis Warrington, Abdul H. Fauq, Daniel McCormick, & Elliott Richelson. (2001). Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats. European Journal of Pharmacology. 428(2). 227–233. 28 indexed citations
20.
Boules, Mona, Lewis Warrington, Jennifer A. Stewart, et al.. (2001). Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties. Brain Research. 919(1). 1–11. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leif H. Lindstr�m Breakdown of academic impact, for papers by B.I. Diamond Breakdown of academic impact, for papers by Celine Teo Breakdown of academic impact, for papers by Kenneth B. Kashkin Breakdown of academic impact, for papers by J. Bollen Breakdown of academic impact, for papers by Dennis Sweitzer Breakdown of academic impact, for papers by John Scott Carman Breakdown of academic impact, for papers by Joseph Pultz Breakdown of academic impact, for papers by Yu-Ping Ning Breakdown of academic impact, for papers by Robyn McAskill
Rankless by CCL
2026